Category Archives: Cell Therapy

Los Angeles, CA (PRWEB) May 25, 2013 IBISWorld estimates that revenue for the Cell Therapy industry will grow at an average annual rate of 28.7% to $1.0 billion in the five years to 2013, including growth of 17.9% in 2013. From 2002 and 2008, no new cell therapy products were introduced, according to IBISWorld industry analyst Kevin Culbert, causing relatively modest growth during that period. In the years since, however, the Food and Drug Administration (FDA) has approved six new products. This factor contributed to the industry's fast growth during the five years to 2013. In 2011, the release of Dendreon's Provenge contributed to revenue growth of 59.5% during the year. The product got a significant boost when Medicare announced that it would cover the cost of reimbursement. In spite of this, the treatment's reception was expected to be considerably greater. Slow adoption was partially caused by the treatment's high sticker price (due to its high cost of development), a factor that has led many doctors to use alternative treatments, Culbert says. Industry operators have spent billions of dollars trying to develop a blockbuster treatment that will yield billions of dollars in return. Wage costs contribute significantly to the Cell … Continue reading →

Invasive procedures for removing non-melanoma skin cancers such as freezing or surgery may soon be a thing of the past. A Queensland researcher may have found a new, less invasive way to treat the disease, which affects approximately 133,100* people in the state each year. Dr Graham Leggatt of The University of Queensland Diamantina Institute, based at Translational Research Institute, is investigating anti-cancer immune cells as an alternative therapeutic option for non-melanoma skin cancer. His work is being supported by a $100,000 Cancer Council Queensland research grant. Dr Leggatt is thrilled with the announcement. "Thanks to the support of Cancer Council Queensland, we will now be able to establish the role of immune cell therapy in clearing advanced non-melanoma skin cancers," he said. Cancer Council Queensland CEO Professor Jeff Dunn congratulated Dr Leggatt and The University of Queensland Diamantina Institute for looking for new ways to treat non-melanoma skin cancers. This research is particularly relevant in our country, and here in Queensland, where we have the highest rates of skin cancer in the world, he said. As a result, non-melanoma skin cancer, which includes both squamous cell carcinoma and basal cell carcinoma, is the most commonly diagnosed cancer in Australia … Continue reading →

FAQ: Is Cell Therapy an outpatient procedure By: Phil Grindstone … Continue reading →

CLEARWATER, Fla., May 20, 2013 /PRNewswire/ -- Sports Medicine is always at the forefront of innovative medical technology. Athletes are constantly striving to improve. Records are broken as humans run faster, jump higher, and strive for higher levels of performance. Athletes expose their bodies to more wear and tear as performance increases. Scientific training principles and diet have changed drastically over time. Technological breakthroughs have also impacted the rehabilitation process. The use of regenerative medicine has grown significantly in recent years. The popularity of Platelet-Rich-Plasma (PRP) has escalated as many high profile elite athletes from a diverse array of sports have opted for this treatment. The likes of Kobe Bryant, Rafael Nadal, and Tiger Woods garner ample press coverage when they are treated for injuries. Stem Cell Therapy becomes headlines when Peyton Manning undergoes this treatment. The goal of regenerative medicine therapies is to aid the body to heal itself. Understanding and accepting stem cell therapies for athletic injuries and sports medicine is gathering keen interest. Dr. Dennis Lox, http://www.drlox.com a Sports and Regenerative Medicine Physician in the Tampa Bay Florida area, comments that the scientific backdrop of cell signaling and inflammatory mediators has led to a new understanding of … Continue reading →

GOODIE MOB Live On BET (Cell Therapy/They Dont Dance No Mo) GOODIE MOB LIVE ON BET PERFORMING(Cell Therapy/They Dont Dance No Mo) By: JROOKZ ENT … Continue reading →

Susie discusses her combination cell therapy from Dr Harry Adelson for her spine pain Susie discusses her combined cell treatment from Dr Harry Adelson for her spine pain. Dr Adelson practices in Park City, Utah and has been performing proloth... By: Harry Adelson … Continue reading →

ALLENDALE, N.J. and WASHINGTON, May 13, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS), a leader in the emerging cellular therapy industry, and its subsidiary, Progenitor Cell Therapy, LLC ("PCT"), an internationally recognized contract development and manufacturing organization, announced today that PCT has entered into a Cell Therapy Processing Customer Agreement with MedStar Georgetown University Hospital in Washington, D.C. to provide autologous and allogeneic cellular therapy services for cellular products provided by MedStar Georgetown University Hospital ("MGUH") and deliver resulting cellular therapy products to MGUH for patient care. In April, Georgetown's Lombardi Comprehensive Cancer Center, part of MedStar Georgetown University Hospital, and the John Theurer Cancer Center, part of Hackensack University Medical Center ("HackensackUMC") in Hackensack, N.J., announced the establishment of an oncology affiliation arrangement between them to enhance patient access to innovative clinical trials, and is a significant step towards developing a clinical, translational and basic science cancer research consortium. In its agreement with PCT, MedStar Georgetown University Hospital will use the services of PCT for processing and storage of peripheral blood progenitor cells, donor leukocytes, bone marrow and cord blood, as well as requested assaying and storage of cellular therapy product, and retrieval and transportation logistics. "Akin to … Continue reading →

ALLENDALE, N.J. and WASHINGTON, May 13, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS), a leader in the emerging cellular therapy industry, and its subsidiary, Progenitor Cell Therapy, LLC ("PCT"), an internationally recognized contract development and manufacturing organization, announced today that PCT has entered into a Cell Therapy Processing Customer Agreement with MedStar Georgetown University Hospital in Washington, D.C. to provide autologous and allogeneic cellular therapy services for cellular products provided by MedStar Georgetown University Hospital ("MGUH") and deliver resulting cellular therapy products to MGUH for patient care. In April, Georgetown's Lombardi Comprehensive Cancer Center, part of MedStar Georgetown University Hospital, and the John Theurer Cancer Center, part of Hackensack University Medical Center ("HackensackUMC") in Hackensack, N.J., announced the establishment of an oncology affiliation arrangement between them to enhance patient access to innovative clinical trials, and is a significant step towards developing a clinical, translational and basic science cancer research consortium. In its agreement with PCT, MedStar Georgetown University Hospital will use the services of PCT for processing and storage of peripheral blood progenitor cells, donor leukocytes, bone marrow and cord blood, as well as requested assaying and storage of cellular therapy product, and retrieval and transportation logistics. "Akin to … Continue reading →

Milwaukee, WI (PRWEB) May 10, 2013 The American Society of Gene & Cell Therapy (ASGCT) is honored to recognize Dr. Sonia Skarlatos, PhD, and Dr. Catherine McKeon, PhD as the recipients of the Distinguished Service Award at the Societys 16th Annual Meeting. This award recognizes an ASGCT member or group that has consistently fostered and enhanced the field of genetic and cellular therapy. The award presentation will begin on Friday, May 17th, at 8:00am in Ballroom E-J at the Salt Palace Convention Center. Dr. Skarlatos, the Deputy Director of the Division of Cardiovascular Sciences with National Heart, Lung, and Blood Institute is credited for her development in various educational programming designed to support gene and cell therapy investigators as well as ensuring certified good manufacturing practices (GMP) grade vectors are available to researchers. Dr. Skarlatos was also instrumental in the conception and implementation of gene therapy programming within the NHLBI. Dr. McKeon serves as the Senior Advisor for Genetic Research at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Dr. McKeon organized one of the first Requests for Application of research centered on gene transfer and gene therapy. Her participation in gene therapy symposia during the 1990s … Continue reading →

Bharat Book Presents: Cell Therapy Technologies, Markets and Companies For More Information Kindly Visit On : http://www.bharatbook.com/market-research-reports/healthcare-market-research-report/cell-therapy-technologies-markets-and-companies.html Summary This... By: Deepa Kamath … Continue reading →